​

Myriad Genetics (MYGN) Stock Forecast, Price Target & Predictions

OverviewRevenueOwnershipFinancialsChartTranscripts

MYGN Stock Forecast

Myriad Genetics (MYGN) stock forecast, based on 28 Wall Street analysts, predicts a 12-month average price target of $10.88, with a high of $18.00 and a low of $6.00. This represents a 109.63% increase from the last price of $5.19.

$5 $10 $15 $20 $25 $30 High: $18 Avg: $10.88 Low: $6 Last Closed Price: $5.19

MYGN Stock Rating

Myriad Genetics stock's rating consensus is Hold, based on 28 Wall Street analysts. The breakdown includes 0 Strong Buy (0.00%), 8 Buy (28.57%), 17 Hold (60.71%), 3 Sell (10.71%), and 0 Strong Sell (0.00%).

Hold
Total 28 0 3 17 8 Strong Sell Sell Hold Buy Strong Buy

MYGN Price Target Upside V Benchmarks

TypeNameUpside
StockMyriad Genetics109.63%
SectorHealthcare Stocks 23.68%
IndustryDiagnostics & Research Stocks22.21%

Price Target Trends

1M3M12M
# Anlaysts-311
Avg Price Target-$10.33$21.36
Last Closing Price$5.19$5.19$5.19
Upside/Downside-99.04%311.56%
Ratings Trends
DateStrong BuyBuyHoldSellStrong SellTotal
Jun, 253191216
May, 255361217
Apr, 255451217
Mar, 254451216
Feb, 254361216
Analyst Price Target Forecasts
DateAnalystCompanyPrice TargetPrice when PublishedPrice Target/Price when PublishedPrice Target/Last Closing Price
May 07, 2025Bill BonelloCraig-Hallum$18.00$7.27147.59%246.82%
May 07, 2025Lu LiUBS$7.00$7.27-3.71%34.87%
May 07, 2025Brandon CouillardWells Fargo$6.00$7.27-17.47%15.61%
Mar 12, 2025Piper Sandler$12.50$10.4120.08%140.85%
Mar 04, 2025Piper Sandler$11.50$10.4210.36%121.58%
Dec 09, 2024Puneet SoudaLeerink Partners$21.00$15.1538.61%304.62%
Oct 14, 2024Sung Ji NamScotiabank$34.00$24.6737.82%555.11%
Sep 19, 2024Tejas SavantMorgan Stanley$32.00$28.4712.40%516.57%
Aug 27, 2024Brandon CouillardWells Fargo$35.00$27.5027.27%574.37%
Aug 07, 2024Subbu NambiGuggenheim$29.00$25.9611.71%458.77%
Analyst Rating Forecasts
DateCompanyPrevious RatingNew RatingRating Change
May 21, 2025ScotiabankSector OutperformSector Performdowngrade
May 07, 2025Craig-HallumBuyBuyhold
May 07, 2025UBSNeutralNeutralhold
May 07, 2025Wells FargoOverweightCautiousdowngrade
Mar 12, 2025Piper SandlerNeutralOverweightupgrade
Dec 09, 2024Leerink PartnersOutperformMarket Performdowngrade
Oct 14, 2024ScotiabankSector OutperformSector Outperformhold
Sep 19, 2024Morgan StanleyEqual-Weightinitialise
Aug 27, 2024Wells FargoOverweightinitialise
Aug 13, 2024ScotiabankOutperformOutperformhold

Financial Forecast

EPS Forecast

$-4 $-3 $-2 $-1 $0 $1 $2 Dec 20 Dec 21 Dec 22 Dec 23 Dec 24 Dec 25 Dec 26 Dec 27 Dec 28
Dec 20Dec 21Dec 22Dec 23Dec 24Dec 25Dec 26Dec 27Dec 28
Reported$-2.99$-0.35$-1.39$-3.18-----
Avg Forecast$-0.19$-0.73$-0.34$-0.30$0.13$0.15$0.37$0.62$0.73
High Forecast$-0.19$-0.59$-0.33$-0.29$0.15$0.35$1.33$0.62$0.74
Low Forecast$-0.19$-0.86$-0.36$-0.31$0.12$-0.24$-0.45$0.61$0.72
Surprise %1473.68%-52.05%308.82%960.00%-----

Revenue Forecast

$550M $650M $750M $850M $950M $1B Dec 20 Dec 21 Dec 22 Dec 23 Dec 24 Dec 25 Dec 26 Dec 27 Dec 28
Dec 20Dec 21Dec 22Dec 23Dec 24Dec 25Dec 26Dec 27Dec 28
Reported$557.00M$690.60M$678.40M$753.20M-----
Avg Forecast$639.35M$691.23M$670.07M$751.44M$839.85M$876.33M$955.37M$998.09M$1.03B
High Forecast$646.31M$698.75M$689.86M$752.10M$842.95M$885.04M$959.12M$1.00B$1.04B
Low Forecast$627.23M$678.12M$655.62M$750.03M$836.98M$865.74M$951.62M$992.91M$1.01B
Surprise %-12.88%-0.09%1.24%0.23%-----

Net Income Forecast

$-2B $-1B $-700M $-300M $100M $500M Dec 20 Dec 21 Dec 22 Dec 23 Dec 24 Dec 25 Dec 26 Dec 27 Dec 28
Dec 20Dec 21Dec 22Dec 23Dec 24Dec 25Dec 26Dec 27Dec 28
Reported$-223.70M$-27.20M$-112.00M$-263.30M-----
Avg Forecast$-1.18B$-47.96M$-35.67M$-263.30M$11.05M$4.40M$-11.72M$50.94M$60.82M
High Forecast$-940.62M$-28.53M$-17.71M$-138.45M$12.28M$28.58M$109.79M$51.60M$61.60M
Low Forecast$-1.41B$-67.39M$-53.63M$-388.15M$9.82M$-19.78M$-37.56M$50.14M$59.86M
Surprise %-80.97%-43.28%213.96%------

MYGN Forecast FAQ

Is Myriad Genetics stock a buy?

Myriad Genetics stock has a consensus rating of Hold, based on 28 Wall Street analysts. The rating breakdown includes 0 Strong Buy, 8 Buy, 17 Hold, 3 Sell, and 0 Strong Sell, reflecting a consensus that Myriad Genetics is a neutral investment for most analysts.

What is Myriad Genetics's price target?

Myriad Genetics's price target, set by 28 Wall Street analysts, averages $10.88 over the next 12 months. The price target range spans from $6 at the low end to $18 at the high end, suggesting a potential 109.63% change from the previous closing price of $5.19.

How does Myriad Genetics stock forecast compare to its benchmarks?

Myriad Genetics's stock forecast shows a 109.63% upside, outperforming the average forecast for the healthcare stocks sector (23.68%) and outperforming the diagnostics & research stocks industry (22.21%).

What is the breakdown of analyst ratings for Myriad Genetics over the past three months?

  • June 2025: 18.75% Strong Buy, 6.25% Buy, 56.25% Hold, 6.25% Sell, 12.50% Strong Sell.
  • May 2025: 29.41% Strong Buy, 17.65% Buy, 35.29% Hold, 5.88% Sell, 11.76% Strong Sell.
  • April 2025: 29.41% Strong Buy, 23.53% Buy, 29.41% Hold, 5.88% Sell, 11.76% Strong Sell.

What is Myriad Genetics’s EPS forecast?

Myriad Genetics's average annual EPS forecast for its fiscal year ending in December 2024 is $0.13, marking a -104.09% decrease from the reported $-3.18 in 2023. Estimates for the following years are $0.15 in 2025, $0.37 in 2026, $0.62 in 2027, and $0.73 in 2028.

What is Myriad Genetics’s revenue forecast?

Myriad Genetics's average annual revenue forecast for its fiscal year ending in December 2024 is $839.85M, reflecting a 11.50% increase from the reported $753.2M in 2023. The forecast for 2025 is $876.33M, followed by $955.37M for 2026, $998.09M for 2027, and $1.03B for 2028.

What is Myriad Genetics’s net income forecast?

Myriad Genetics's net income forecast for the fiscal year ending in December 2024 stands at $11.05M, representing a -104.20% decrease from the reported $-263M in 2023. Projections indicate $4.4M in 2025, $-11.72M in 2026, $50.94M in 2027, and $60.82M in 2028.